营收超57亿！川宁生物，业绩爆发

医药行业底部已经明朗，不少头部企业业绩已经率先回暖。叠加集采因素已经消化，医药企业的估值亟需修复。近期，抗生素中间体龙头企业川宁生物发布了2024年财报，财报显示，报告期内川宁生物实现营收57.58亿元，同比增长19.38%；实现净利润14.00亿元，同比增长48.88%。 $川宁生物(301301)$

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":429169879097488,"tweetId":"429169879097488","gmtCreate":1745800510903,"gmtModify":1745804101152,"author":{"id":3570515415388899,"idStr":"3570515415388899","authorId":3570515415388899,"authorIdStr":"3570515415388899","name":"侃见财经","avatar":"https://static.tigerbbs.com/58a85251003e9d3ca730ab71b7738ce8","vip":6,"userType":6,"introduction":"侃见财经官方账号","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3070,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[{"img":"https://static.tigerbbs.com/d4d28568610931164bc435b41e4cab89"}],"title":"营收超57亿！川宁生物，业绩爆发","html":"<html><head></head><body>医药行业底部已经明朗，不少头部企业业绩已经率先回暖。叠加集采因素已经消化，医药企业的估值亟需修复。近期，抗生素中间体龙头企业川宁生物发布了2024年财报，财报显示，报告期内川宁生物实现营收57.58亿元，同比增长19.38%；实现净利润14.00亿元，同比增长48.88%。 <a href=\"https://laohu8.com/S/301301\">$川宁生物(301301)$</a>\n<video poster=\"https://static.tigerbbs.com/d4d28568610931164bc435b41e4cab89\" tg-width=\"1280\" tg-height=\"720\" class=\"ql-video\" controls=\"true\" controlslist=\"nodownload\" playsinline=\"true\" webkit-playsinline=\"true\">\n <source src=\"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/1a7db2171397757910953926924/A9asJKqMF3cA.mp4\">\n</video>\n</body></html>","htmlText":"<html><head></head><body>医药行业底部已经明朗，不少头部企业业绩已经率先回暖。叠加集采因素已经消化，医药企业的估值亟需修复。近期，抗生素中间体龙头企业川宁生物发布了2024年财报，财报显示，报告期内川宁生物实现营收57.58亿元，同比增长19.38%；实现净利润14.00亿元，同比增长48.88%。 <a href=\"https://laohu8.com/S/301301\">$川宁生物(301301)$</a>\n<video poster=\"https://static.tigerbbs.com/d4d28568610931164bc435b41e4cab89\" tg-width=\"1280\" tg-height=\"720\" class=\"ql-video\" controls=\"true\" controlslist=\"nodownload\" playsinline=\"true\" webkit-playsinline=\"true\">\n <source src=\"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/1a7db2171397757910953926924/A9asJKqMF3cA.mp4\">\n</video>\n</body></html>","text":"医药行业底部已经明朗，不少头部企业业绩已经率先回暖。叠加集采因素已经消化，医药企业的估值亟需修复。近期，抗生素中间体龙头企业川宁生物发布了2024年财报，财报显示，报告期内川宁生物实现营收57.58亿元，同比增长19.38%；实现净利润14.00亿元，同比增长48.88%。 $川宁生物(301301)$","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/429169879097488","repostId":0,"isVote":1,"tweetType":2,"object":{"id":"3cf202f233084e1dae9d5f376eec07f0","videoUrl":"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/1a7db2171397757910953926924/A9asJKqMF3cA.mp4","poster":"https://static.tigerbbs.com/d4d28568610931164bc435b41e4cab89","desc":""},"viewCount":138,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["301301"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":255,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/429169879097488"}